Related Experiment Video
Updated: Jun 6, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Partners in crime: Genes within an amplicon collude to globally deregulate chromatin in lymphoma
Dong-Joon Min1, Jonathan D Licht
1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
Abstract:
In this issue of Cancer Cell, Rui et al. identify JAK2 and JMJDC2 as two contiguous, coamplified oncogenes in primary mediastinal B cell and Hodgkin lymphoma. Together, JAK2 and JMJD2C induce major changes in chromatin structure and gene expression. Targeting these proteins with small molecules represents a new avenue for therapy.
Insights
Researchers found two coamplified oncogenes, JAK2 and JMJD2C, in specific lymphomas. Targeting these genes offers a new therapeutic strategy for these B-cell cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Primary mediastinal B-cell lymphoma and Hodgkin lymphoma are aggressive non-Hodgkin lymphomas.
- The genetic underpinnings of these lymphomas are complex and involve alterations in oncogenes and tumor suppressor genes.
Discussion:
- Rui et al. identify Janus kinase 2 (JAK2) and Jumonji domain-containing protein 2C (JMJD2C) as coamplified oncogenes in primary mediastinal B-cell lymphoma and Hodgkin lymphoma.
- These two genes are located contiguously on chromosome 9p24.1, a region frequently amplified in these malignancies.
- The coamplification of JAK2 and JMJD2C leads to significant alterations in chromatin structure and gene expression, driving oncogenesis.
Key Insights:
- JAK2 and JMJD2C are identified as key oncogenes in primary mediastinal B-cell lymphoma and Hodgkin lymphoma.
- Coamplification of these genes induces substantial changes in chromatin organization and gene expression profiles.
- This discovery highlights a novel genetic vulnerability in these B-cell lymphomas.
Outlook:
- Targeting JAK2 and JMJD2C with small molecule inhibitors presents a promising new therapeutic avenue.
- Further research into the precise mechanisms of JAK2 and JMJD2C cooperation may reveal additional therapeutic targets.
- Developing targeted therapies could improve outcomes for patients with these challenging lymphomas.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the timing and level of...
Abnormal Proliferation
Coordination of Gene Expression Processes in Bacteria
Inheritance of Chromatin Structures
